首页|疏血通注射液联合奥拉西坦对脑梗死患者血液流变学及血清Hcy水平变化的影响

疏血通注射液联合奥拉西坦对脑梗死患者血液流变学及血清Hcy水平变化的影响

扫码查看
目的 探讨奥拉西坦联合疏血通注射液对脑梗死患者血液流变学及血清Hcy水平变化的影响.方法 选取60例脑梗死患者,随机分为2组,观察组30例给予奥拉西坦联合疏血通注射液治疗,对照组30例给予单纯疏血通注射液治疗,比较2组血液流变学及血清Hcy水平.结果 治疗后,观察组的血液流变学指标和血清Hcy水平均低于对照组,差异有统计学意义(P<0.05);观察组治疗效果明显优于对照组,差异有统计学意义(P<0.05),观察组神经功能缺损评分明显优于对照组,2组差异具有统计学意义(P<0.05);观察组并发症例数2例(6.7%),显著低于对照组的9例(30.0%),2组比较差异有统计学意义(P<0.05).结论 对脑梗死患者应用奥拉西坦联合疏血通注射液治疗,可有效改善血液流变学指标,降低血清Hcy水平.
Effect of shuxuetong injection combined with oxiracetam on hemorheology and serum Hcy levels in patients with cerebral infarction
Objective To investigate the effects of oxiracetam combined with Shuxuetong injection on hemorheology and serum Hcy levels in patients with cerebral infarction. Methods 60 patients with cerebral infarction were randomly divided into 2 groups, 30 cases in the observation group and were treated with oxiracetam combined with Shuxuetong injection. 30 cases in the control group were treated with Shuxuetong injection. The hemorheology and serum Hcy levels in the two groups were compared. Results After treatment, the hemorheological indexes and serum Hcy levels in the observation group were lower than those in the control group (P<0.05). The treatment effect of the observation group was better than that of the control group (P<0.05). The scores of neurological deficits in the observation group were significantly better than those in the control group (P<0.05). The number of complications in the observation group was 2 cases, the incidence of complications was 6.7%, which were significantly lower than 9(30.0%) in the control group, the differences between the two groups was statistically significant (P<0.05). Conclusion The application of oxiracetam combined with Shuxuetong injection in patients with cerebral infarction can effectively improve the hemorheology and reduce the serum Hcy level.

cerebral infarctionoxiracetamShuxuetong injectionHcy levelhemorheology

王世琳、吴凤刚

展开 >

天津市职业病防治院 神经内科,天津 300011

脑梗死 奥拉西坦 疏血通注射液 Hcy 血液流变学

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(8)
  • 1
  • 13